Refine your search

Search Results within category "Infectious Diseases & Immune System"

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories

Suggestions within category "Infectious Diseases & Immune System"


14 Study Matches

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of CC-220 in Subjects with Active Systemic Lupus Erythematosus

This study is for patients with SLE (systemic lupus erythematosus) to determine the effectiveness and safety of drug CC-220 on improving SLE and to see how well the body tolerates the medication.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03161483
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of Systemic Lupus Erythematosus
Exclusion Criteria:
Diagnosis of Fibromyalgia
Active or history of recurrent bacterial, viral or fungal infections
History of latent or active tuberculosis
History of blood clots in the past year
Infectious Diseases & Immune System, Arthritis & Rheumatic Diseases, Muscle & Bone
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site For VIOLET

Site For VIOLET
Nancy Campbell RN at ncampbell1@pennstatehealth.psu.edu or 717-531-1707, ext=3
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Admission to ICU with acute risk factors for Acute Respiratory Distress Syndrome (ARDS): Pneumonia, Aspiration, smoke inhalation, lung contusion, hypoxemia, intubation
shock
sepsis
pancreatitis
Vit. D deficiency
Exclusion Criteria:
unable to take Vit D by mouth
blood Calcium levels > 10.2
known kidney stone in past 1 year
Do Not Rescusitate orders (DNR)
prisoner
Infectious Diseases & Immune System, Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects with Hereditary Angioedema

This study is for patients diagnosed with Type 1 or Type 2 Hereditary Angioedema (HAE) and have suffered HAE attacks (episodes of swelling), and are either not using HAE medications to prevent HAE attacks or for medical or personal choice reasons have decided to discontinue using these medications. This research is being done to compare the effects of two different doses of BCX7353 compared to placebo. Placebo-containing capsules look exactly like BCX7353 capsules, but do not contain BCX7353 or any other drug. The Sponsor will test two different doses of BCX7353 to see if BCX7353 is able to prevent or reduce the number of swelling episodes or attacks in people with HAE when taken every day by mouth, compared to placebo. This research study will also assess the safety of the new drug BCX7353.
Terri Smith at tjs97@psu.edu or 717-531-4513
All
All
This study is NOT accepting healthy volunteers
NCT03485911
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Adults & Children 12 years or older
Diagnoses with HAE Type 1 or Type 2
2 or more HAE attacks per month
Exclusion Criteria:
Pregnant females or planning on becoming pregnant or nursing
Anticipated use of short-term prophylaxis for pre-planned procedure or surgery
Chest pain, heart attack, passing out or significant heart beat abnormality
Pacemaker or defibrillator implanted
Family history of sudden cardiac death not related to HAE
Infectious Diseases & Immune System, Allergies
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Exploring Facilitators and Barriers to Self-Initiated Sexually Transmitted Infection Testing among College Student

The purpose of this study is to identify modifiable facilitators and barriers to self-initiated sexually transmitted infection (STI) testing among college students aged 18 – 24 years. This study will entail filling out a demographic and sexual history questionnaire, and a private face-to-face interview.
Oluwamuyiwa Adebayo at DAresearch@psu.edu or 814-867-4656
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
aged 18 – 24
able to speak and understand English language fluently
able to provide written informed consent
engaged in sexual activity in the past 6 months
fit into either study Group I (self-initiated STI testing) or Group II (never tested for STI) or Group III (Clinician-initiated)
Exclusion Criteria:
Not meeting all the inclusion criteria
Infectious Diseases & Immune System, Men's Health, Women's Health
  Email this study information to me
  Contact the study team
  Show all 5 locations

Study Locations

Hide all locations
Location
Altoona, PA
Harrisburg, PA
Hershey, PA
State College, PA
Williamsport, PA

Site For CLOVERS

Site For CLOVERS
Nancy Campbell RN at ncampbell1@pennstatehealth.psu.edu or 717-531-1707, ext=3
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT00343402
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age > 18 years
Suspected or confirmed infection
Sepsis induced hypotension
Exclusion Criteria:
> 4 hours from start of hypotension
> 3 L intravenous fluids
Pregnancy
Severe volume depletion
Immediate surgical intervention planned
Infectious Diseases & Immune System, Heart & Vascular
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Evaluation of the Immune Response and Antigenic Signature of Patients with Babesia Infection in Pennsylvania with the Aim of Developing a Rapid Diagnostic Test

We are evaluating patients who have been infected with Babesia. Babesia is a blood parasite that is acquired from ticks. The number of cases seen in Pennsylvania every year has been increasing. We intend to evaluate the blood of patients acutely infected with Babesiosis and compare it to the blood of healthy individuals. We hope to identify proteins in the blood of acutely infected patients that are specific for Babesia that could then be used to create a rapid diagnostic test.
David Ingram at dingram@pennstatehealth.psu.edu or 717-531-8881
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Healthy
18 years or older
Exclusion Criteria:
Active Cancer
History of having your spleen removed
History of liver or kidney disease
HIV
Diabetes
Infectious Diseases & Immune System
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

An Observational, Non-Interventional Study of Patients with Hereditary Angioedema in the United States and Canada (EMPOWER study)

Evaluate real-world effectiveness of drug in patients with hereditary angioedema (HAE). Patient reported attack diaries and patient-reported outcomes (PROs) as well as physician assessments at visits will be used to describe HAE attack rates, treatment patterns, healthcare utilization and patient quality of life.
Joshua Adams at jadams4@pennstatehealth.psu.edu or 717-531-4513
All
All
This study is NOT accepting healthy volunteers
NCT03845400
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Voluntarily able to provide consent
Diagnosis of HAE Type I or Type II
Able to use a mobile device for data collection in the study
Exclusion Criteria:
Participation in any interventional clinical trial at the time of enrollment
Unable to provide consent
Investigator believes patient is not a suitable candidate for the study
Infectious Diseases & Immune System
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

The Role of Obesity on the Phenotype and Function of Human Monocytes and their Role in Atherosclerotic Risk

We are conducting a study that is comparing the distribution of monocyte subsets (i.e. classical, intermediate and non-classical monocyte) between adults aged 55-75 with obesity/metabolic syndrome and healthy controls. The participants will have one screening visit and one study visit, and both will involve a blood draw. Each visit should take an hour or less, and the compensation for this study is $10. Lab results from screening will also be provided to participants at no cost.
Ester Oh at sxo35@psu.edu or 814-867-3720
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
55-75 years old
Non-smoker
BMI between 18.5 – 35 kg/m2
Exclusion Criteria:
Systolic BP > 160 mmHg or diastolic BP > 100 mmHg
Fasting glucose > 126 mg/dL
Use of cholesterol/lipid-lowering medications
Use of anti-hypertensive medications
Use of glucose lowering medications
Infectious Diseases & Immune System, Heart & Vascular, Prevention
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

AN OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY OF DAILY ORAL BCX7353 IN SUBJECTS WITH TYPE I AND II HEREDITARY ANGIOEDEMA

This is a clinical trial to determine the effectiveness of a daily oral medication in prevention of swelling attacks in patients with Hereditary Angioedema.
Joshua Adams at jadams4@pennstatehealth.psu.edu
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03472040
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Type I or II HAE
Used androgen therapy for prophylaxis of HAE episodes in past 12 months
Greater than or equal 40 kg
Access to appropriate rescue medication for HAE attacks
Exclusion Criteria:
Pregnant, breastfeeding, or planned pregnancy
Prior enrollment in BCX 7353 study
Known family history of sudden cardiac death
Infectious Diseases & Immune System, Allergies
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Centre County COVID-19 Data 4 Action Study

The purpose of this research is to evaluate the extent of COVID-19 risk and perceived risk among Centre County residents and students, and how those risks evolve from the time isolation guidelines were implemented through a return to normal functioning. Participants in this research will complete an electronic survey with questions about their demographic, about their exposure to COVID-19, and about how COVID-19 has affected their health and work/education. Data from this research will be used to inform Centre County planning authorities and the Pennsylvania State University about the needs of communities, including needs for information dissemination and for potentially actionable, local interventions in response to the COVID-19 pandemic.
Susan McHale at src-ssri@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
At least 18 years of age.
Currently living in Centre County, PA.
Expect to continue living in Centre County, PA (through at least Sept 2020)
Capable of providing your own informed consent.
Exclusion Criteria:
No additional exclusion criteria beyond those required for inclusion.
Infectious Diseases & Immune System, Men's Health, Women's Health
  Email this study information to me
  Contact the study team

A phase III, randomized, double blind, parallel group, placebo controlled, international, multicentre study to assess efficacy and safety of Cx601, adult allogeneic expanded adipose-derived stem cells (eASC), for the treatment of complex perianal fistula(s) in patients with Crohn’s disease over a period of 24 weeks and a follow-up period up to 52 weeks. ADMIRE-CD II study.

This study is for patients with Crohn's disease which involves an investigational new drug to treat perianal fistulas in patients with Crohn’s disease (CD). The purpose of this study is to find out: 1) How well the study drug works at a single dose compared to a placebo; 2) how safe and tolerable the study drug is in patients with fistulizing CD.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03279081
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of Crohn's Disease for at least 6 months
Presence of complex perianal fistulas
Clinically controlled, non active or mildly active CD during the last 6 months
Patients whose perianal fistulas were previously treated and have shown an inadequate response
Exclusion Criteria:
Any major surgery of the GI tract within past 6 months
Patients without prior specific treatment for perianal complex fistulas
Patients with diverting stomas
Patients with active, uncontrolled infection requiring IV antibiotics
Patients with allergies or hypersensitivity to penicillin or aminoglycosides, local anesthetics or MRI contrast
Infectious Diseases & Immune System, Digestive Systems & Liver Disease
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Inflammatory, Behavioral and Neural Markers of Anhedonia in Major Depressive Disorder

The purpose of this study is to investigate the underlying biological causes of the loss of pleasure in individuals diagnosed with depression. This study will examine brain, behavioral, and inflammatory markers of depression. Participants will answer questions, give blood and saliva, undergo fMRI and perform computer tasks. The study is a 1 time appointment lasting 3hrs and participants will be compensated $130. The study is also recruiting healthy controls with no history of major mental illnesses.
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Major Depressive Disorder
Failed two lines of anti depressant treatment
Between 18-65 years of age
Exclusion Criteria:
Any metallic implant
Bipolar Disorder or Psychotic Disorder
Heavy alcohol or recreational drug use
Inflammatory disease like Lupus, Rheumatoid Arthritis
Infectious Diseases & Immune System, Prevention, Mental & Behavioral Health
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Study of Angelica gigas dietary supplements (Cogni.Q) and potential effects on human immune cells

This human study will test the impact of dietary supplement vegicaps containing Korean Angelica root extract on 2 types of human immune cells: neutrophils that kill bacteria and other germs and natural killer (NK) cells that kill virus-infected cells and cancers. We had done an earlier study with Korean Angelica supplement and discovered even a single dose of it increased blood neutrophils and NK cells within 24 h. In the new study, Korean Angelica capsules (Cogni.Q) will be compared head-to-head with dummy (placebo) capsules. This is to make sure the immune boosting actions are really from the Korean Angelica supplement. Approximately 40 men will take part in this research study at Hershey Medical Center.
Male
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Male subjects 21 to 65 years of age
Subjects weighing between 110 to 240 pounds; their body mass index (BMI) should be in the range of 19=< BMI >=30
Subjects having normal hepatic, renal function as assessed by history, physical and clinical chemistry analysis (CMP eGFR).
Subjects with normal blood pressure (systolic below 120 mm Hg and diastolic below 80 mm Hg)
Exclusion Criteria:
Subjects positive for HIV, HBV and HCV (self-reported)
Subjects taking any kind of prescription medications regularly or within 10 days of the study will be excluded.
Subjects taking dietary or herbal supplements that contain AGN (e.g. Cogni.Q, Decursinol-50, Ache Action, Fast-Acting Joint Formula, EstroG-100/Profemin) within 10 days of the study.
Non-English-speaking subjects
Infectious Diseases & Immune System, Blood Disorders, Food & Nutrition
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Survey to Estimate the Socio-Economic Impact of the Novel Corona Virus (COVID-19) Pandemic

We are experiencing global outbreak of coronavirus (COVID-19) recently. Millions of people are suffering and dying every day, in spite of putting our best efforts. We are doing this survey to understand people’s reaction to this situation. The survey will ask about your knowledge, practices and worries. Your response will help us to understand how to better control these situations. Your feedback is highly important to us, as we need to find out the best way to stop the disease from spreading and killing thousands of lives, and to reduce the stress among the population.
Pritish Mondal at pmondal@pennstatehealth.psu.edu or 717-897-0652
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
General population
Adult
Exclusion Criteria:
Age below 18 years
Mentally impaired
Infectious Diseases & Immune System, Prevention, Lung Disease & Asthma
  Email this study information to me
  Contact the study team